3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Phase 1
1
Status
Completed
3
Not yet recruiting
2
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
41
INDUSTRY
3
NETWORK
1
Study Type
Interventional
3
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Uterine Cervical Dysplasia
1
Triple Negative Breast Neoplasms
1
Squamous Intraepithelial Lesions
1
Prostatic Neoplasms
1
Interventions
Paclitaxel
490
Carboplatin
436
Gemcitabine
394
Docetaxel
385
Cisplatin
360
pembrolizumab
344
Bevacizumab
335
Nivolumab
261
Pemetrexed
243
Capecitabine
221
Dexamethasone
213
Fluorouracil
211
Rituximab
203
Trastuzumab
193
Cyclophosphamide
190
Oxaliplatin
160
Erlotinib Hydrochloride
147
Ipilimumab
145
atezolizumab
144
Prednisone
144
Cetuximab
142
Irinotecan
139
Leucovorin
130
Doxorubicin
130
Sorafenib
120
Lenalidomide
119
Bortezomib
118
Sunitinib
107
Everolimus
93
130-nm albumin-bound paclitaxel
92
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Completed
×
INDUSTRY
×
Electroporation
×
Clear all
NCT04972097
2026-06-02
PRESERVE
Angiodynamics, Inc.
Phase NA
Completed
121 enrolled
19 charts
NCT03185013
2023-07-27
REVEAL 1
Inovio Pharmaceuticals
Phase 3
Completed
201 enrolled
23 charts
NCT02531425
2023-05-15
TNBC
OncoSec Medical Incorporated
Phase 1
Completed
10 enrolled